Valence8 Us LP Cassava Sciences Inc Transaction History
Valence8 Us LP
- $241 Billion
- Q3 2024
A detailed history of Valence8 Us LP transactions in Cassava Sciences Inc stock. As of the latest transaction made, Valence8 Us LP holds 14,100 shares of SAVA stock, worth $36,519. This represents 0.17% of its overall portfolio holdings.
Number of Shares
14,100Holding current value
$36,519% of portfolio
0.17%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$8.34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$6.53 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$3.01 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.61 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.5 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $104M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...